UASI’s Post

Is there a way to determine which medication will work better for a specific patient? How can physicians best prescribe medicine and treatments to their patients? Find out in this module from the @AmerMedicalAssn. #pharmacogenomics https://lnkd.in/gi2WkHES

Is there a way to determine which medication will work better for a specific patient? How can physicians best prescribe medicine and treatments to their patients? Find out in this module from the American Medical Association. #pharmacogenomics https://lnkd.in/g8y5696S

Streamlining Care: Targeted Drug-Drug Interaction Alerts in the ICUs What are CDSS? Clinical decision support systems (CDSS) are computer programs integrated into electronic health records (EHRs) to aid healthcare professionals in making clinical decisions. They can provide various functionalities, including: Drug-drug interaction alerts: Highlighting potential adverse reactions when mixing medications. Dosage guidance: Recommending appropriate medication dosages based on patient factors. Clinical reminders: Alerting clinicians to recommended tests or screenings based on patient history. A New Approach: Tailored Drug-Drug Interaction Alerts A recent randomized trial conducted in Dutch ICUs investigated the impact of ICU-tailored drug-drug interaction (DDI) alerts. Here's what they found: Reduced High-Risk Drug Combinations: Compared to the control group, ICUs with tailored DDI alerts saw a significant decrease in administrations of potentially dangerous drug combinations (26.2 vs. 35.6 per 1000 administrations). Focus on Relevance: This research highlights the potential of CDSS customization to improve patient care. By focusing on high-risk interactions within a specific clinical environment, it can empower healthcare professionals to make informed decisions. #healthcare #patientcare #criticalcare #medicalinnovation #CDSS

Is there a way to determine which medication will work better for a specific patient? How can physicians best prescribe medicine and treatments to their patients? Find out in this module from the @AmerMedicalAssn. #pharmacogenomics https://lnkd.in/gtqjvUrb

Today we have published a guest blog by the National Wound Care Strategy Programme (NWCSP) that explains how they have been using GMDN Codes, Terms and Definitions to align groups of wound management products, leading to higher standards of care and safety. Dr Barry Daniels, Senior Clinical Lead at the GMDN AGENCY (Global Medical Device Nomenclature Agency), has been leading the GMDN implementation on the NWCSP. He said: “Our involvement with the NWCSP is very important as it is one of the first clinically orientated implementations of the categorisation functionality in the Global Medical Device Nomenclature, applied to data captured from multiple sources including Regulatory and Health Service. The GMDN is seen as an internationally-accepted standard that can be used as a basis for a more granular clinically-relevant level of classification. The ongoing collaboration is providing very useful feedback into the GMDN Term development process to improve the utility and effectiveness of the Global Medical Device Nomenclature.” You can read the full blog here: https://lnkd.in/e5FxJfT6

Is there a way to determine which medication will work better for a specific patient? How can physicians best prescribe medicine and treatments to their patients? Find out in this module from the American Medical Association. #pharmacogenomics https://lnkd.in/gqTtDfkW

Chart Reviews can help you save money, time, and can help you plan your study's development protocol. Learn more about how Chart Reviews can inform early research and development. https://lnkd.in/eCXmjhmj #chartreview #clinicalresearch #CRO

A new MDCG guidance document got released in March 2024 discussing about clinical investigation plan, location, sample size, statistical analysis, ethical consideration, publication process etc. Do take a look at: MDCG 2024-3 Guidance on content of the Clinical Investigation Plan for clinical investigations of medical devices. #mdr #mdcg #clinical investigation

Post Market Clinical Follow Up (PMCF) studies, as per the International Medical Device Regulators Forum (IMDRF), involve the systematic collection and analysis of clinical data from the use of a medical device following its commercial distribution. These studies aim to assess the device's performance and safety in real-world settings, often focusing on long- term outcomes and rare adverse events that may not have been captured during premarket clinical evaluations. PMCF studies are crucial for ensuring ongoing monitoring of device safety and effectiveness throughout its lifecycle.

The new MDCG guidance on the Clinical Evaluation of Orphan Medical Devices os here! Orphan devices address the needs of a limited number of individuals who have few diagnostic or therapeutic options, making them essential in meeting otherwise unmet medical needs. These devices encounter unique challenges, ranging from limited pre-market clinical data to post-market clinical follow-up. This new guidance represents a significant step forward in addressing these challenges and ensuring these critical devices reach the patients who need them. #MedicalDevices #OrphanDevices #ClinicalEvaluation #MDCG #Healthcare